MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA
Modified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. We have previously observed that MVAΔ008, an MVA lacking the gene that codes for interleukin-18 binding protein, significantly increases CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo |
| Language: | Inglés |
| Published: |
Elsevier
2021
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/10777 https://www.sciencedirect.com/science/article/abs/pii/S016158902100242X https://doi.org/10.1016/j.molimm.2021.08.004 |
| _version_ | 1855484654122958848 |
|---|---|
| author | Del Medico Zajac, Maria Paula Molinari, Maria Paula Gravisaco, María José Maizon, Daniel Omar Moron, Victor Gabriel Gherardi, Maria Magdalena Calamante, Gabriela |
| author_browse | Calamante, Gabriela Del Medico Zajac, Maria Paula Gherardi, Maria Magdalena Gravisaco, María José Maizon, Daniel Omar Molinari, Maria Paula Moron, Victor Gabriel |
| author_facet | Del Medico Zajac, Maria Paula Molinari, Maria Paula Gravisaco, María José Maizon, Daniel Omar Moron, Victor Gabriel Gherardi, Maria Magdalena Calamante, Gabriela |
| author_sort | Del Medico Zajac, Maria Paula |
| collection | INTA Digital |
| description | Modified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. We have previously observed that MVAΔ008, an MVA lacking the gene that codes for interleukin-18 binding protein, significantly increases CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV antigens. However, the efficacy of this vector against pathogens or tumor cells remains unclear. Thus, the aim of this study was to evaluate the cellular immune response and the protection induced by recombinant MVAs encoding the model antigen ovalbumin (OVA). We used the MO5 melanoma tumor model (OVA-expressing tumor) as an approach for evaluating the vector-induced efficacy. Our results show that MVAΔ008-OVA (optimized vector) induced higher in vivo specific cytotoxicity and ex vivo T-cell IFN-γ responses against OVA than the conventional MVA vector. Importantly, the recombinant vectors were capable of controlling MO5 tumor growth. Indeed, the administration of MVAΔ008-OVA or MVA-OVA in prophylactic and therapeutic schemes provided total protection and longer survival of mice, respectively. Overall, our results demonstrate the improved immunogenicity and the protective capacity of MVAΔ008 against a heterologous model antigen. These findings suggest that MVAΔ008 constitutes an excellent candidate for vaccine development against pathogens or cancer therapy. |
| format | Artículo |
| id | INTA10777 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | INTA107772021-11-15T14:28:34Z MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA Del Medico Zajac, Maria Paula Molinari, Maria Paula Gravisaco, María José Maizon, Daniel Omar Moron, Victor Gabriel Gherardi, Maria Magdalena Calamante, Gabriela Vacuna Vectores Respuesta Inmunológica Genética Vaccines Vectors Immune Response Genetics Modified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. We have previously observed that MVAΔ008, an MVA lacking the gene that codes for interleukin-18 binding protein, significantly increases CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV antigens. However, the efficacy of this vector against pathogens or tumor cells remains unclear. Thus, the aim of this study was to evaluate the cellular immune response and the protection induced by recombinant MVAs encoding the model antigen ovalbumin (OVA). We used the MO5 melanoma tumor model (OVA-expressing tumor) as an approach for evaluating the vector-induced efficacy. Our results show that MVAΔ008-OVA (optimized vector) induced higher in vivo specific cytotoxicity and ex vivo T-cell IFN-γ responses against OVA than the conventional MVA vector. Importantly, the recombinant vectors were capable of controlling MO5 tumor growth. Indeed, the administration of MVAΔ008-OVA or MVA-OVA in prophylactic and therapeutic schemes provided total protection and longer survival of mice, respectively. Overall, our results demonstrate the improved immunogenicity and the protective capacity of MVAΔ008 against a heterologous model antigen. These findings suggest that MVAΔ008 constitutes an excellent candidate for vaccine development against pathogens or cancer therapy. Instituto de Biotecnología Fil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Molinari, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Molinari, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gravisaco, María José. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Gravisaco, María José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Maizon, Daniel Omar Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Anguil; Argentina Fil: Moron, Victor Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Moron, Victor Gabriel. Universidad Nacional de Córdoba.Facultad de Ciencias Químicas. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Gherardi, Maria Magdalena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina Fil: Gherardi, Maria Magdalena. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina. Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentina Fil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina 2021-11-15T14:24:41Z 2021-11-15T14:24:41Z 2021-11 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/10777 https://www.sciencedirect.com/science/article/abs/pii/S016158902100242X 0161-5890 https://doi.org/10.1016/j.molimm.2021.08.004 eng info:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular. info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Molecular Immunology 139 : 115-122 (November 2021) |
| spellingShingle | Vacuna Vectores Respuesta Inmunológica Genética Vaccines Vectors Immune Response Genetics Del Medico Zajac, Maria Paula Molinari, Maria Paula Gravisaco, María José Maizon, Daniel Omar Moron, Victor Gabriel Gherardi, Maria Magdalena Calamante, Gabriela MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title | MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title_full | MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title_fullStr | MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title_full_unstemmed | MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title_short | MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA |
| title_sort | mvaδ008 viral vector encoding the model protein ova induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional mva |
| topic | Vacuna Vectores Respuesta Inmunológica Genética Vaccines Vectors Immune Response Genetics |
| url | http://hdl.handle.net/20.500.12123/10777 https://www.sciencedirect.com/science/article/abs/pii/S016158902100242X https://doi.org/10.1016/j.molimm.2021.08.004 |
| work_keys_str_mv | AT delmedicozajacmariapaula mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT molinarimariapaula mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT gravisacomariajose mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT maizondanielomar mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT moronvictorgabriel mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT gherardimariamagdalena mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva AT calamantegabriela mvad008viralvectorencodingthemodelproteinovainducesimprovedimmuneresponseagainsttheheterologousantigenandequallevelsofprotectioninamicetumormodelthantheconventionalmva |